Inventiva S.A.

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

2026-08-05 04:19:09

Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

2026-07-30 16:00:00

Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As a result, the corrected version shall read as follows:

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

2026-07-29 16:00:00

Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues.

ADAR1 Capital Management LLC Sells 535,448 Shares of Inventiva S.A. Sponsored ADR $IVA

2026-07-29 03:47:54

ADAR1 Capital Management LLC decreased its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA) by 19.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,174,398 shares of the company's stock after selling 535,448 shares during the

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

2026-07-09 16:20:00

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “Combined Transaction”) through the issuance of approximately 15.7 million new warrants (bons de souscription d'actions) (the "New EIB Warrants") to the European Investment Bank (the "EIB") and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the “Legacy EIB Tranche B Warrants”) that were not repurchased in the Combined Transaction.

Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026

2026-07-02 16:00:00

Daix (France),  New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders' Meeting.

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

2026-06-29 10:36:04

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Claret Capital Partners participates in €130m financing for Inventiva

2026-06-16 05:12:33

Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing Latest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners ('Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ: IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), a common and progressive chronic liver disease.